## The HbA1c Network Structure, Performance and Rules

Cas Weykamp, Network Coordinator Queen Beatrix Hospital, Winterswijk, The Netherlands Scientific Meeting CIRME, Milan, 6 November 2007




## Working Group Standardization HbA1c

Developing and Approval of Reference Method

Longterm Worldwide Maintaining Of Reference Method


Network





Mono-S, Sweden

#### Definition of the Analyte

# **Traceability Chain**







# **Questions on Statistics**

1.Value Assignment with a Network How? Expanded Uncertainty?

2. Basis for Approval Network Labs?

3. Basis Approval of Calibrators/Controls?

4. Master Eqaution (Relation DCM's) Statistical Basis?


# Questions -> Statistical Tools

Software Model

Papers
1. Value Assignment and Uncertainty
Accred Qual Assur 2006;11:319-28

2. Statistical Rules for Networks J Test Eval 2006;34:128-34

3. Relations between Networks




# Intercomparison Study

A set with <u>different sample types</u> is sent to Network Laboratories And DCM Laboratories

Assay results are processed according to the Statistical Model of the Network

And evaluated

## Organisations How do they warrant Continuity? Life Cycle of a President



## **Calibrators**

## **How does Network warrant Continuity?**

Life Cycle of a Batch Calibrators (Calibrators are prepared from pure HbA1c and pure HbA0)

<u>Year 1</u>	<u>Year 2</u>	<u>Year 3</u>	Year 4
"New Calibrator"	"Calibrator"	"Old Calibrator"	"Spare"
Analysed As Sample	Calibrator Set	Analysed As Sample	
Batch Approved?	To calibrate Reference Method	Stability?	

## Controls

## **How does Network warrant Continuity?**

#### Life Cycle of Controls

(Controls are prepared from Whole Blood)

<u>Year 1</u>	<u>Year 2</u>	<u>Year 3</u>	<u>Year 4</u>
"Unknown Sample"	"Control"	"Control"	"Spare"
Analysed As Sample	Analysed As Sample	Analysed As Sample	
Laboratory Approved?	Stability? -Sample -Network	Stability? -Sample -Network	


# **Samples Intercomparison Study**

# **Calibrators**

- \* Calibrator set (calibrate RM)
- \* New Calibrators (approve new batch)
- \* Old Calibrators (check stability)

# **Patient Samples**

- \* Unknown HbA1c (Approval Labs)
- \* Known HbA1c (Controls)



# Calibrators 2001 – 2006

Paper with data submitted

\*Number of Batches Manufactured 10 Batches (6 HbA1c levels each)


#### \*New Calibrators

One occasion difference between calculated (from pure HbA1c/HbA0) and measured HbA1c exceeded criterion; batch discarded

#### \*Old Calibrators

Difference between calculated and measured HbA1c never exceeded criteria

Conclusion: Calibrators can be manufactured Reproducibly and are stable on storage



# Controls 2001 - 2006


Paper with data submitted

\* Number of Batches manufactured 12 Batches ((low/High HbA1c each batch)


#### \*Difference in Outcome Difference in measured HbA1c after 1 and 2 years storage in comparison to initial value never exceeded criterion

#### \*Conclusion

Double Conclusion: Cotrols are stable on storage and the Reference System is stable




**Collaboration with and guided** By remarks of the Network Labs




**Administration** 

All Exercises are done twice A year: this maintains skills And proves if logistics and Administration works well



#### **Amsterdam-1 Study**


Approval Lab Elliptic (Study Amsterdam - 1)



#### Narrow Escape for Three Network Laboratories!

### **Amsterdam 2 Study**


Approval Lab Elliptic (Study Amsterdam - 2)



#### **Excellent Performance of all Network Labs**

## Los Angeles 2 Study


Paper with these data submitted



# One laboratory fails

# **Network Rules**

- A Network Laboratory loses the status of approved laboratory when it fails (or does not submit results) in two consecutive Intercomparison Studies
- \* A candidate network laboratory gets the status of approved network laboratory when it passes two consecutive intercomparison studies



# **Consensus Statement HbA1c**

3. "HbA1c results are to be reported Worldwide in IFCC units (mmol/mol) and Derived NGSP units (%), using the IFCC-NGSP Master Equation"

### Master Equation is Important:


- To report according to Consensus Statement
- To relate old studies (DCCT) to new units vice versa

# Clin Chem 2004; 50: 166-74

IFCC Reference System for Measurement of Hemoglobin A<sub>1c</sub> in Human Blood and the National Standardization Schemes in the United States, Japan, and Sweden: A Method-Comparison Study

 Wieland Hoelzel,<sup>1</sup> Cas Weykamp,<sup>2</sup> Jan-Olof Jeppsson,<sup>3</sup> Kor Miedema,<sup>4\*</sup> John R. Barr,<sup>5</sup> Ian Goodall,<sup>6</sup> Tadao Hoshino,<sup>7</sup> W. Garry John,<sup>8</sup> Uwe Kobold,<sup>1</sup> Randie Little,<sup>9</sup> Andrea Mosca,<sup>10</sup> Pierluigi Mauri,<sup>11</sup> Rita Paroni,<sup>12</sup> Fransiscus Susanto,<sup>13</sup> Izumu Takei,<sup>14</sup> Linda Thienpont,<sup>15</sup> Masao Umemoto,<sup>16</sup> and Hsiao-Mei Wiedmeyer,<sup>9</sup> on behalf of the IFCC Working Group on HbA<sub>1C</sub> Standardization

# **Master Equations**



# **Monitoring Master Equation**

Samples Intercomparison Study are analysed by both -The IFCC Network laboratories -The DCM network laboraotories (NGSP network, JDS/JSCC, Mono-S

This allows to monitor the consistency Of the Master Equation

### Data of 12 independant Studies

(paper with these data submitted)

## $\mathbf{Y} = \mathbf{a}\mathbf{x} + \mathbf{b}$


Study	NGSP	JDS	Mono-S
Marrakech	y=0.926x+2.14	y= 0.934x+1.76	y=1.008x+0.90
Chicago	y=0.926x+2.05	y=0.926x+1.67	y=0.941x+1.09
Kyoto-1	y=0.906x+2.21	y=0.920x+1.78	y=1.002x+0.78
Kyoto-2	y=0.912x+2.17	y=0.943x+1.68	y=0.968x+1.15
Barcelona-1	y=0.905x+2.23	y=0.912x+1.78	y=0.964x+0.95
Barcelona-2	y=0.897x+2.21	y=0.916x+1.70	y=0.963x+0.92
LA-1	y=0.901x+2.24	y=0.880x+1.95	y=0.949x+1.10
LA-2	y=0.907x+2.23	y=0.911x+1.73	y=0.997x+0.91
Orlando-1	y=0.913x+2.15	y=0.892x+1.84	y=0.961x+1.01
Orlando-2	y=0.924X+2.07	y=0.928X+1.63	y=0.998X+0.81

ME


y=0.915+2.15 y=0.927x+1.73

y=0.989X+0.88

#### Shewhart Chart NGSP outcome in %HbA1c at IFCC-RM = 53 mmol/mol




Grey Zone: Area with significant difference from published ME




Shewhart Chart JDS/JSCC outcome in %HbA1c at IFCC-RM = 53 mmol/mol

X-axis: The subsequent studies in 6 years Y-axis: JDS/JSCC percentage HbA1c Grey Zone: Area with significant difference from published ME



Shewhart Chart Mono S outcome in %HbA1c at IFCC-RM = 53 mmol/mol

X-axis: The subsequent studies in 6 years Y-axis: JDS/JSCC percentage HbA1c Grey Zone: Area with significant difference from published ME



# **Advantages Network**

# \* Backbone to get a RM started

\* Continuity

\* Quality

In the Development of a Reference System ...... .....a network is the Backbone of Research:

> -Stimulus of a group -Finding Resources (Sponsors, EU) -Coordination Executive Work

..... And thus the best guarantee of Success In creating a such a reference system

# Quality

-Prevention of Blunders (*if a network assigns a value, blunders are excluded*)

-Lowest Uncertainty in top Traceability Chain (uncertainty decreases when n increases)

-Systematic (re) approval of labs (Intercomparison Studies with sound statistical rules)

-Central batchmanagement calibrators (Manufacture and Validity check)

# Continuity

For global, reliable, long-lasting standardisation continuity of the reference system is essential

#### A Network meets this requirement of Continuity

-No problem when some labs stop in a network of 15 labs

- -Guaranteed availability of calibrators from central stock
- -Updated SOP
- -Maintenance of specific skills
- -Logistic and Administrative System



#### HbA1c Reference Method

MAGBIPPALF COSTERTIVM FECT



#### **Network: the Fundament for Eternal Traceability**

#### Thanks to the Network of HbA1c Reference Laboratories:

Germany

Prof. Hans Reinauer and Dr. Patricia Kaiser, INSTAND, Düsseldorf Dr. Uwe Kobold, Roche, Penzberg Dr. Franziscus Susanto, DDZ, Düsseldorf

Italy

Prof. Andrea Mosca, Dr. Renata Paleari and Prof. Donatella Caruso, CIRME, Milan

Japan

Dr. Tadao Hoshino, IBM, Kanagawa Dr. Masao Umemoto, SRC, Kawasaki Prof. Izumi Takei, SKMU, Tokyo, Japan

The Netherlands Dr. Robbert Slingerland, IKW, Zwolle, The Netherlands Dr. Cas Weykamp, SKB, Winterswijk

USA

Dr. Hubert Vesper, CDC, Atlanta, GA Dr. Cindy Deng and Dr. Jim Albarella, Siemens MS, Norwood Dr. Randie Little, UMSM, Missouri